Airway diseases
Clinical trials session
ALERT: COPD
Aims : Including the ALERT sessions (Abstracts Leading to Evolution in
Respiratory Medicine Trials), these formats showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, session chairs and viewers will take part lively discussions on the presented trials.
Methods :
General respiratory patient care, Public health, Pulmonary rehabilitation
11:15
Introduction
1
RCT205
11:20
Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial
A. Yousuf(Oxford (Oxfordshire), United Kingdom)
COI
2
11:27
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
L. Puente Maestu(Madrid, Spain)
COI
3
11:34
The relationship between eosinophils and reduction in major adverse cardiac events in ETHOS
M. Bafadhel(London, United Kingdom)
COI
4
11:41
Wrap-up by discussant and discussion
G. Brusselle(Ghent, Belgium)
COI
5
RCT209
12:06
Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
S. Andreas(Immenhausen, Germany)
COI
6
12:13
RCT Abstract - Tailored psychological intervention for anxiety/depression in people with COPD (TANDEM): a randomised controlled trial.
S. Taylor(London, United Kingdom)
COI
7
12:20
Wrap-up by discussant and discussion
J. Wedzicha(London, United Kingdom)
COI
8
RCT212
12:40
Closing remarks
9
RCT213
. . .
